Sravanthi Cheeti

1.0k total citations
28 papers, 522 citations indexed

About

Sravanthi Cheeti is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Sravanthi Cheeti has authored 28 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Sravanthi Cheeti's work include Hedgehog Signaling Pathway Studies (6 papers), Drug Transport and Resistance Mechanisms (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sravanthi Cheeti is often cited by papers focused on Hedgehog Signaling Pathway Studies (6 papers), Drug Transport and Resistance Mechanisms (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sravanthi Cheeti collaborates with scholars based in United States, United Kingdom and Spain. Sravanthi Cheeti's co-authors include Jin Y. Jin, Richard Graham, Patricia LoRusso, Sharmila Rajan, Nageshwar Budha, Mark J. Dresser, Jennifer A. Low, Chi‐Ho Lee, Bert L. Lum and Charles M. Rudin and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and International Journal of Pharmaceutics.

In The Last Decade

Sravanthi Cheeti

27 papers receiving 489 citations

Peers

Countries citing papers authored by Sravanthi Cheeti

Since Specialization

Citations

This map shows the geographic impact of Sravanthi Cheeti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sravanthi Cheeti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sravanthi Cheeti more than expected).

Fields of papers citing papers by Sravanthi Cheeti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sravanthi Cheeti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sravanthi Cheeti. The network helps show where Sravanthi Cheeti may publish in the future.

Co-authorship network of co-authors of Sravanthi Cheeti

This figure shows the co-authorship network connecting the top 25 collaborators of Sravanthi Cheeti. A scholar is included among the top collaborators of Sravanthi Cheeti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sravanthi Cheeti. Sravanthi Cheeti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer 2024 ·The Journal of Clinical Pharmacology ·Nastya Kassir, David McDougall, (unknown), (unknown), Shaun S. Kumar, (unknown), Thorsten Ruf, Sravanthi Cheeti, (unknown)	2
2	Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib 2024 ·Drug Metabolism and Pharmacokinetics ·Christine M. Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, (unknown), Rucha Sane, Nastya Kassir, (unknown)	2
3	Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations 2024 ·Clinical and Translational Science ·Julia Suchomel, (unknown), Doreen Anders, (unknown), (unknown), Rucha Sane, Astrid Scalori, Sunil Sharma, Sravanthi Cheeti	1
4	Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors 2024 ·Frontiers in Artificial Intelligence ·(unknown), (unknown), Sravanthi Cheeti, (unknown), (unknown), (unknown), (unknown), (unknown)	1
5	Integrating Dynamic in vitro Systems and Mechanistic Absorption Modeling: Case Study of Pralsetinib 2024 ·Journal of Pharmaceutical Sciences ·Michael Dolton, Christine Bowman, (unknown), Sravanthi Cheeti, (unknown), Nastya Kassir, Yuan Chen, Jia Liu, Po‐Chang Chiang	0
6	An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer 2023 ·Clinical Cancer Research ·Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez, Jennifer M. Giltnane, Mary Gates, Ching‐Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, (unknown), Heather M. Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W. Humke, Aditya Bardia	7
7	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer 2022 ·Breast Cancer Research and Treatment ·Aditya Bardia, Ingrid A. Mayer, Eric P. Winer, Hannah M. Linden, X. Cynthia, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching‐Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer M. Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris T. Chan, Komal Jhaveri	14
8	Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study 2022 ·Targeted Oncology ·Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne‐Marie Langevin, Isabelle Aerts, Lisa Howell, Soledad Gallego, Claudia Rössig, Amy Smith, Darshak Patel, Leonardo Pereira, Sravanthi Cheeti, Luna Musib, Katherine E. Hutchinson, Clare Devlin, Ronald J. Bernardi, Birgit Geoerger	30
9	GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study 2019 ·Drug Metabolism and Disposition ·(unknown), Kenta Yoshida, Sravanthi Cheeti, Buyun Chen, Roland Morley, Iris T. Chan, Srikumar Sahasranaman, Lichuan Liu	28
10	Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects 2018 ·Pharmaceutical Research ·Sravanthi Cheeti, Hao Hou, Eric Nelson, (unknown), Buyun Chen, Roland Morley, Mary Gates, Luna Musib, Sandhya Girish, Srikumar Sahasranaman, Lichuan Liu	6
11	Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid – Case Study of GDC-0810 2018 ·Pharmaceutical Research ·Hao Hou, Jia Wei, Lichuan Liu, Sravanthi Cheeti, Jane Li, (unknown), Karthik Nagapudi	18
12	Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects 2018 ·The Journal of Clinical Pharmacology ·Lichuan Liu, Sravanthi Cheeti, Kenta Yoshida, Edna F. Choo, (unknown), Buyun Chen, Mary Gates, Stina Mui Singel, Roland Morley, Joseph A. Ware, Srikumar Sahasranaman	29
13	Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment 2017 ·Cancer Chemotherapy and Pharmacology ·Ghassan K. Abou‐Alfa, Lionel D. Lewis, Patricia LoRusso, Michael L. Maitland, Priya Chandra, Sravanthi Cheeti, Dawn Colburn, Sarah Williams, Brian Simmons, Richard Graham	24
14	Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer 2013 ·Cancer Research ·Dejan Juric, Cristina Saura, Andrés Cervantes, Carla Kurkjian, (unknown), Jasgit C. Sachdev, (unknown), IE Krop, Mafalda Oliveira, Sandra Sanabria, Sravanthi Cheeti, (unknown), (unknown), (unknown), Hema Parmar, (unknown), (unknown), José Baselga	11
15	Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding 2011 ·Clinical Cancer Research ·Richard Graham, Bert L. Lum, Sravanthi Cheeti, Jin Y. Jin, Karin Jorga, Daniel D. Von Hoff, Charles M. Rudin, Josina C. Reddy, Jennifer A. Low, Patricia LoRusso	97
16	Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors 2011 ·Clinical Cancer Research ·Patricia LoRusso, Antonio Jimeno, Grace K. Dy, Alex A. Adjei, Jordan Berlin, Lawrence Leichman, Jennifer A. Low, Dawn Colburn, Ilsung Chang, Sravanthi Cheeti, Jin Y. Jin, Richard Graham	74
17	Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry 2010 ·Journal of Chromatography B ·(unknown), (unknown), Richard Graham, Sravanthi Cheeti, (unknown), Luca Matassa, Scott Reuschel, Minjie Meng, (unknown), (unknown), B L Lum, Patrick J. Rudewicz, Cornelis E. C. A. Hop	35
18	A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties 2008 ·Bioorganic & Medicinal Chemistry Letters ·Ingrid Choong, Iana M. Serafimova, (unknown), David E. Stockett, (unknown), Sravanthi Cheeti, (unknown), Bruce J. Fahr, (unknown), Michelle R. Arkin, Duncan Walker, Ute Hoch	10
19	Modifications of the isonipecotic acid fragment of SNS-032: Analogs with improved permeability and lower efflux ratio 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Bruce J. Fahr, David E. Stockett, (unknown), Sravanthi Cheeti, Iana M. Serafimova, (unknown), (unknown), Duncan Walker, Ute Hoch, Ingrid Choong	5
20	The role of monocarboxylate transporters in uptake of lactic acid in HeLa cells 2006 ·International Journal of Pharmaceutics ·Sravanthi Cheeti, (unknown), Chi‐Ho Lee	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact